Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05188170
Other study ID # IRB-61916
Secondary ID PEDSHEMAML000764
Status Recruiting
Phase Phase 1
First received
Last updated
Start date November 21, 2022
Est. completion date December 2026

Study information

Verified date January 2024
Source Stanford University
Contact Nancy Sweeters
Phone 650-724-4042
Email nks2016@stanford.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Protocol is designed to evaluate a niclosamide dose escalation scale in combination with cytarabine as a therapeutic modality for pediatric subjects with relapsed/refractory acute myeloid leukemia.


Recruitment information / eligibility

Status Recruiting
Enrollment 16
Est. completion date December 2026
Est. primary completion date July 2025
Accepts healthy volunteers No
Gender All
Age group 2 Years to 25 Years
Eligibility Inclusion Criteria: - Prior morphologically confirmed diagnosis of AML based on WHO Criteria - Has previously failed all available and suitable therapies for AML Disease relapse or the presence of refractory disease after = 2 cycles of chemotherapy must be documented by bone marrow (BM) examination demonstrating > 5% blasts in the BM not attributable to another cause. Administration of hydroxyurea 10 to 20 mg/kg/day PO (maximum 1000 mg PO BID) to control high WBC count is permitted. - Age = 2 and = 25 years - Body surface area (BSA) = 2.10 m2, calculated per the Mostellar formula - Must be able to tolerate po or ng medications. - Performance status: - Subject age = 16 years old: Lansky score = 50 > 16 years old: Karnofsky score = 50% - Life expectancy of greater than 4 weeks - Platelets = 10,000/mm3 (for subjects with platelets < 10,000/mm3 at baseline, platelet transfusion support is allowed) - Serum creatinine = 2.0 mg/dL or estimated creatinine clearance = 30 mL/min (Cockcroft Gault) within 14 days prior to treatment initiation - Total bilirubin = 2.0 x Institutional upper limit of normal (ULN) within 14 days prior to treatment initiation, unless the elevation is due primarily to elevated unconjugated hyperbilirubinemia secondary to Gilbert's syndrome or hemolysis or non hepatic origin, and not to liver dysfunction - SGOT (AST) = 3.0 x ULN and SGPT (ALT) = 3.0 x ULN within 14 days prior to treatment initiation - Females of reproductive potential (WOCBP) must have a negative pregnancy test within 14 days prior to study treatment. - WOCBP must agree to use adequate contraception (eg, hormonal or barrier methods of birth control; abstinence; sterilized partner) for the duration of study participation - Men only: Men must agree to use adequate contraception (eg, hormonal or barrier methods of birth control; abstinence; sterilized partner) prior to the study treatment (from date of consent), for the duration of study participation, and 30 days after completion of niclosamide administration - Ability to understand the purpose and risks of the study and the willingness to sign a written informed consent document containing an authorization to use protected health information (in accordance with national and local subject privacy regulations Exclusion Criteria: - Received anticancer therapy (chemotherapy, immunotherapy, radiotherapy, or investigational therapy) within 2 weeks prior to starting study treatment. Administration of hydroxyurea 10 to 20 mg/kg/day PO (maximum 1000 mg PO BID) to control high WBC is permitted. - Receiving any other investigational agents. - Unresolved toxicities due to prior anticancer therapy, defined as not having resolved to Grade 0 or 1 (by CTCAE version 5 criteria), unless otherwise defined in the inclusion/exclusion criteria with the exception of alopecia - Acute promyelocytic leukemia (French American British Class M3 AML) - Known active central nervous system (CNS) leukemia; subjects can enroll on study if CNS disease can be cleared with intrathecal chemotherapy, in the judgement of the treating physician - Prior bone marrow transplant presenting with active uncontrolled graft versus host disease (GvHD) - Known congenital bleeding disorders, including but not limited to hemophilia - Known active uncontrolled systemic infection - Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel, uncontrolled symptomatic inflammatory bowel disease or ulcerative colitis, or partial or complete bowel obstruction, at the time of study entry - Inability to receive administration of niclosamide in the available formulation(s) - Uncontrolled intercurrent illness including, but not limited to, uncontrolled active infection, or psychiatric illness/social situations that would limit compliance with study requirements - Lactating or pregnant female - Known active hepatitis C

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Niclosamide
Niclosamide will be administered orally for 14 days. Each dose will be followed by backbone chemotherapy

Locations

Country Name City State
United States Stanford University Palo Alto California

Sponsors (1)

Lead Sponsor Collaborator
Stanford University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Dose-limiting toxicity Dose-limiting toxicities (DLTs) are defined as any events = Grade 3 that are at least possibly, probably, or definitely related to niclosamide treatment 30 days
Secondary Efficacy of niclosamide treatment clinical response Clinical response is defined as any of the following.
Complete response (CR) = < 5% blasts in BM, with no evidence of extramedullary disease.
Partial response (PR) = = 5% to = 25% blasts in BM with decrease in BM blast percentage by 50%, and no evidence of extramedullary disease.
Resistant disease with clinical benefit (RD-CB) = either = 5% to = 25% blasts in BM OR a decrease in blast percentage by 50%, either with no evidence of extramedullary disease.
No response (NR) is defined as BM disease that does not fall into the above categories
8 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT04240002 - A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) Phase 1/Phase 2
Completed NCT02626715 - Reduced-Intensity Conditioning (RIC) and Myeloablative Conditioning (MAC) for HSCT in AML/MDS Phase 2
Completed NCT05488613 - Healthcare Resource Utilization in Adults Diagnosed With Acute Myeloid Leukemia (AML)
Completed NCT02265731 - Study Evaluating Venetoclax in Subjects With Hematological Malignancies Phase 1/Phase 2
Terminated NCT02927938 - Leukemia Stem Cell Detection in Acute Myeloid Leukemia Phase 3
Completed NCT01772953 - Treosulfan/Fludarabine/Low Dose TBI as a Preparative Regimen for Children With AML/MDS Undergoing Allo HCT Phase 2
Recruiting NCT03188874 - Clinical AML Registry and Biomaterial Database of the Study Alliance Leukemia (SAL)
Completed NCT00071006 - AG-013736 (Axitinib) In Patients With Poor Prognosis Acute Myeloid Leukemia (AML) Or Myelodysplastic Syndrome (MDS) Phase 2
Completed NCT04079296 - A Study Investigating the Safety, Tolerability and Efficacy of ASP7517 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) and Relapsed/Refractory Higher Risk Myelodysplastic Syndrome (MDS) Phase 1/Phase 2
Completed NCT04509622 - A Study of Oral Venetoclax Tablet in Combination With Subcutaneous Low-Dose Cytarabine (LDAC) Injection to Assess Adverse Events in Adult Japanese Participants With Acute Myeloid Leukemia (AML) Phase 3
Withdrawn NCT03699384 - Safety and Clinical Activity Study of Combination Azacitidine and Avelumab in Patients With Acute Myeloid Leukemia (AML) and Minimal Residual Disease (MRD) Phase 1/Phase 2
Recruiting NCT03613532 - Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN Phase 1
Terminated NCT02259348 - Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation Phase 2
Completed NCT02252107 - 10-day Decitabine, Fludarabine and 2 Gray TBI as Conditioning Strategy for Poor and Very Poor Risk AML in CR1 Phase 2
Terminated NCT01463410 - Accuracy Testing of the Chromosomal Aberration and Gene Mutation Markers of the AMLProfiler N/A
Completed NCT01242774 - Safety & Efficacy Study of Oral Panobinostat (LBH589) With Chemotherapy in Patients < 65 Years Old With Acute Myeloid Leukemia (AML) Phase 1
Terminated NCT02134782 - Yoga Fatigue Study N/A
Completed NCT01685619 - AML-MDS Novel Prognostic Tests Clinical Study
Completed NCT03625505 - A Study to Assess Safety and Efficacy of Venetoclax in Combination With Gilteritinib in Participants With Relapsed/Refractory Acute Myeloid Leukemia Phase 1
Active, not recruiting NCT04266795 - A Study of Pevonedistat and Venetoclax Combined With Azacitidine to Treat Acute Myeloid Leukemia (AML) in Adults Unable to Receive Intensive Chemotherapy Phase 2